Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jacob Magee Sands, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Roberts TJ, Sellars MC, Sands JM, Jacobson JO. A Perfect Storm Averted: Flawed Systems, a Dropped Ball, and Cognitive Biases Delay a Critical Diagnosis. JCO Oncol Pract. 2022 Sep 01; OP2200145. PMID: 36049142.
    Citations:    Fields:    
  2. Regis SM, Borondy-Kitts A, McKee AB, Rieger-Christ K, Sands J, Afnan J, McKee BJ. Outcomes of Positive and Suspicious Findings in Clinical Computed Tomography Lung Cancer Screening and the Road Ahead. Ann Am Thorac Soc. 2022 08; 19(8):1371-1378. PMID: 34818144; PMCID: PMC9353952.
    Citations:    Fields:    
  3. Yambayev I, Sullivan TB, Rieger-Christ KM, Servais EL, Stock CT, Quadri SM, Sands JM, Suzuki K, Burks EJ. Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy. Lung Cancer. 2022 09; 171:82-89. PMID: 35932520.
    Citations:    Fields:    Translation:Humans
  4. Wood DE, Kazerooni EA, Aberle D, Berman A, Brown LM, Eapen GA, Ettinger DS, Ferguson JS, Hou L, Kadaria D, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Mazzone P, Merritt RE, Midthun DE, Onaitis M, Pipavath S, Pratt C, Puri V, Raz D, Reddy C, Reid ME, Sandler KL, Sands J, Schabath MB, Studts JL, Tanoue L, Tong BC, Travis WD, Wei B, Westover K, Yang SC, McCullough B, Hughes M. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. J Natl Compr Canc Netw. 2022 07; 20(7):754-764. PMID: 35830884.
    Citations:    Fields:    Translation:HumansPHPublic Health
  5. Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, Osarogiagbon RU, Kozono D. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol. 2022 05 01; 8(5):717-728. PMID: 35297944; PMCID: PMC8931674.
    Citations:    Fields:    Translation:Humans
  6. Raez LE, Danenberg K, Sumarriva D, Usher J, Sands J, Castrellon A, Ferraro P, Milillo A, Huang E, Soon-Shiong P, Reddy S, Danenberg P. Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors. Cancer Drug Resist. 2021; 4(4):1061-1071. PMID: 35582387; PMCID: PMC8992448.
  7. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1441-1464. PMID: 34902832.
    Citations: 11     Fields:    Translation:Humans
  8. Burks EJ, Zhang J, Sullivan TB, Shi X, Sands JM, Regis SM, McKee BJ, McKee AB, Zhang S, Liu H, Liu G, Spira A, Beane J, Lenburg ME, Rieger-Christ KM. Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts. Cancer Treat Res Commun. 2021; 29:100486. PMID: 34794107; PMCID: PMC8713084.
    Citations:    Fields:    Translation:Humans
  9. Singh AK, Sands JM. Yet Another Reminder of the Value of Lung Cancer Screening. J Thorac Oncol. 2021 09; 16(9):1437-1439. PMID: 34425996.
    Citations:    Fields:    Translation:HumansPHPublic Health
  10. Shah P, Sands J, Normanno N. The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. Lung Cancer. 2021 10; 160:118-126. PMID: 34500194.
    Citations: 1     Fields:    Translation:Humans
  11. Patel S, Petty WJ, Sands JM. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther Adv Med Oncol. 2021; 13:17588359211020529. PMID: 34104228.
    Citations: 2     
  12. Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer. 2021 07; 157:17-20. PMID: 34052704.
    Citations:    Fields:    Translation:Humans
  13. Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021 06; 13(9):727-734. PMID: 33878954; PMCID: PMC8293026.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  14. Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021 07; 22(4):313-323.e1. PMID: 33745865; PMCID: PMC8562492.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  15. Knelson EH, Patel SA, Sands JM. PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses. Cancers (Basel). 2021 Feb 10; 13(4). PMID: 33578789.
    Citations: 5     
  16. Sands J, Tammemägi MC, Couraud S, Baldwin DR, Borondy-Kitts A, Yankelevitz D, Lewis J, Grannis F, Kauczor HU, von Stackelberg O, Sequist L, Pastorino U, McKee B. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation. J Thorac Oncol. 2021 01; 16(1):37-53. PMID: 33188913.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  17. Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020 12; 150:90-96. PMID: 33096421.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  18. Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, Jänne PA, Oxnard GR. Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO Precis Oncol. 2020; 4. PMID: 33015530.
    Citations: 4     Fields:    
  19. Sands JM, Daly ME, Lee EQ. Neurologic complications of lung cancer. Cancer. 2020 10 15; 126(20):4455-4465. PMID: 33460079.
    Citations: 1     Fields:    Translation:Humans
  20. Ricciuti B, Naqash AR, Naidoo J, Sehgal K, Miller A, Kehl K, Venkatraman D, Sands J, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Rangachari D, Gainor JF, Costa DB, Rizvi N, Sholl LM, Nishino M, Henick B, Farago AF, Awad MM. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100074. PMID: 34589955; PMCID: PMC8474257.
    Citations: 1     
  21. Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 05; 21(5):645-654. PMID: 32224306.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  22. Sands JM, Milan MSD, Oxnard GR. Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool? J Thorac Oncol. 2020 02; 15(2):163-165. PMID: 32127182.
    Citations:    Fields:    Translation:Humans
  23. Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 2020 02; 140:35-41. PMID: 31855703.
    Citations: 8     Fields:    Translation:Humans
  24. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018 10; 16(10):1171-1182. PMID: 30323087.
    Citations: 72     Fields:    Translation:Humans
  25. Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018 08; 24(8):1143-1150. PMID: 30038220.
    Citations: 102     Fields:    Translation:HumansAnimalsCells
  26. Sands J, Li Q, Hornberger J. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis. Lung Cancer. 2017 08; 110:19-25. PMID: 28676213.
    Citations: 13     Fields:    Translation:Humans
  27. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. PMID: 28736761.
    Citations: 10     Fields:    
  28. Kent M, Zinman L, Girshovich L, Sands J, Vanni A. Combined chemoradiation as primary treatment for invasive male urethral cancer. J Urol. 2015 Feb; 193(2):532-7. PMID: 25088950.
    Citations: 9     Fields:    Translation:Humans
  29. Smith CP, Lee WS, Martial S, Knepper MA, You G, Sands JM, Hediger MA. Cloning and regulation of expression of the rat kidney urea transporter (rUT2). J Clin Invest. 1995 Sep; 96(3):1556-63. PMID: 7657826; PMCID: PMC185781.
    Citations: 22     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Sands's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (100)
Co-Authors (30)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.